Genor Biopharma Releases Its Annual Results for 2020

Significant progresses in IND, clinical development, NDA/BLA, commercialization, BD and financing NDA/BLA progress – GB226 (Geptanolimab) Priority Review for PTCL, GB242 (infliximab (Remicade) …
( read original story …)

---